Comparing the effects of two types of Botox, Dysport and Masport, in improving pain in patients with trigeminal neuralgia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210306050606N3

Enrollment

Registered

2025-11-17

Start date

2025-12-01

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trigeminal neuralgia. Trigeminal neuralgia

Interventions

Intervention 1: Intervention group: Patients receiving Botox Masport. Intervention 2: Intervention group: Patients receiving Botox Dysport.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with drug-resistant trigeminal neuralgia

Exclusion criteria

Exclusion criteria: Patients with coagulation disorders, cardiac, hepatic and renal disease, cancer, pregnant and lactating patients, patients who have responded to medical treatments and symptomatic trigeminal neuralgia (abnormal neurological examination or structural lesion visible by MRI) and comorbidities that may be exacerbated by BTX-A (such as myasthenia gravis or motor neuron disease).

Design outcomes

Primary

Measure	Time frame
Determining and comparing the effects of two types of Botox, Dysport and Masport, in improving pain in patients with trigeminal neuralgia. Timepoint: The first follow-up of the patients will be after one week, and then all patients will be followed up every two weeks for 12 weeks using VAS. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAdeleh Pooyafard

Yazd University of Medical Sciences

a.pooyafard@ssu.ac.ir+98 35 3620 4760

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026